{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T23:20:12Z","timestamp":1793834412996,"version":"4.6.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,3]],"date-time":"2021-11-03T00:00:00Z","timestamp":1635897600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,3]],"date-time":"2021-11-03T00:00:00Z","timestamp":1635897600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Primary lymphoma of the prostate is an exceedingly rare disease, with diffuse large B-cell lymphoma being the most common known subtype in a small number of reported cases. Due to its low prevalence, there has been a chronic lack of targeted diagnostic guidelines and treatment procedures.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>In this article, we report a case of primary diffuse large B-cell lymphoma of the prostate in a 70-year-old Asian man who presented with symptoms of urinary tract obstruction. Histological and immunocytochemical studies of transurethral biopsy of the prostate showed diffuse large B-cell lymphoma. The patient was managed by a combination of eight courses of chemotherapy with a regimen including rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone and radiotherapy. Post-chemotherapy computed tomography scans showed complete remission. He remained disease free, until now, 15\u00a0months after the end of therapy. We also reviewed and analyzed relevant literature to illustrate the diagnosis, treatment, and prognosis of this disease.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Diffuse large B-cell non-Hodgkin\u2019s lymphoma originating in the prostate is a rare and highly aggressive disease that lacks specificity in its clinical presentation and is easily misdiagnosed. This disease should be considered clinically in patients with significant prostate enlargement and insignificant prostate-specific antigen elevation. The diagnosis can be clarified with a prostate puncture biopsy. Chemotherapy is the main treatment for patients and may be supplemented with surgical treatment and radiotherapy.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13256-021-03143-3","type":"journal-article","created":{"date-parts":[[2021,11,3]],"date-time":"2021-11-03T00:03:42Z","timestamp":1635897822000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Primary diffuse large B-cell lymphoma of the prostate: a case report and\u00a0review of the\u00a0literature"],"prefix":"10.1186","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9752-3275","authenticated-orcid":false,"given":"Mengwei","family":"Ren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanli","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,3]]},"reference":[{"key":"3143_CR1","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1016\/S0022-5347(01)67330-0","volume":"153","author":"A Sarris","year":"1995","unstructured":"Sarris A, Dimopoulos M, Pugh W, et\u00a0al. Primary lymphoma of the prostate: good outcome with doxorubicin-based combination chemotherapy. J Urol. 1995;153:1852\u20134.","journal-title":"J Urol"},{"key":"3143_CR2","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.clon.2012.02.004","volume":"24","author":"DH Wright","year":"2012","unstructured":"Wright DH. Pathology of extra-nodal non Hodgkin lymphomas. Clin Oncol (R Coll Radiol). 2012;24:319\u201328.","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"3143_CR3","first-page":"340","volume":"25","author":"XD Zhou","year":"2019","unstructured":"Zhou XD, Qi RX, Feng X, et\u00a0al. Clinicopathological characterization of non-Hodgkin lymphoma of the prostate. Zhonghua Nan Ke Xue. 2019;25:340\u20135.","journal-title":"Zhonghua Nan Ke Xue"},{"key":"3143_CR4","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1002\/(SICI)1097-0142(19980815)83:4<732::AID-CNCR15>3.0.CO;2-T","volume":"83","author":"DG Bostwick","year":"1998","unstructured":"Bostwick DG, Iczkowski KA, Amin MB, et\u00a0al. Malignant lymphoma involving the prostate: report of 62 cases. Cancer. 1998;83:732\u20138.","journal-title":"Cancer"},{"key":"3143_CR5","first-page":"801","volume":"27","author":"LS King","year":"1951","unstructured":"King LS, Cox TR. Lymphosarcoma of the prostate. Am J Pathol. 1951;27:801\u201323.","journal-title":"Am J Pathol"},{"key":"3143_CR6","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1159\/000457117","volume":"10","author":"DE Ezekwudo","year":"2017","unstructured":"Ezekwudo DE, Ogunleye F, Gbadamosi B, et\u00a0al. Primary extranodal diffuse large B-cell lymphoma of the prostate: a case report. Case Rep Oncol. 2017;10:199\u2013204.","journal-title":"Case Rep Oncol"},{"key":"3143_CR7","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s11805-007-0129-1","volume":"4","author":"T Fang","year":"2007","unstructured":"Fang T. Clinical analysis of 29 cases with primary malignant lymphoma of the prostate. Chin J Clin Oncol. 2007;4:129\u201332.","journal-title":"Chin J Clin Oncol"},{"key":"3143_CR8","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/S0022-5347(17)53297-8","volume":"128","author":"WF Whitmore","year":"1982","unstructured":"Whitmore WF, Skarin AT, Rosenthal DS. Urological presentations of non-Hodgkin\u2019s lymphomas. J Urol. 1982;128:953\u20136.","journal-title":"J Urol"},{"key":"3143_CR9","first-page":"621","volume":"94","author":"K Fukutani","year":"2003","unstructured":"Fukutani K, Koyama Y, Fujimori M, et\u00a0al. Primary malignant lymphoma of the prostate: report of a case achieving complete response to combination chemotherapy and review of 22 Japanese cases. Nihon Hinyokika Gakkai zasshi. 2003;94:621\u20135.","journal-title":"Nihon Hinyokika Gakkai zasshi"},{"key":"3143_CR10","unstructured":"Wang N, Tian-Qiang YU, Jia HE, et al. Primary lymphoma of the prostate: one case report and literature review. Chin Gen Pract. 2017;29(v.20;No.548):119\u201321."},{"key":"3143_CR11","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1590\/S1677-55382006000100010","volume":"32","author":"CA Alvarez","year":"2006","unstructured":"Alvarez CA, Rodriguez BI, Perez LA. Primary diffuse large B-cell lymphoma of the prostate in a young patient. Int Braz J Urol. 2006;32:64\u20135.","journal-title":"Int Braz J Urol"},{"key":"3143_CR12","first-page":"412","volume":"16","author":"A Jafari","year":"2019","unstructured":"Jafari A, Mofid B, Tabibi A, Kowsari F. Primary prostate lymphoma managed with combined modality treatment: a case report. Urol J. 2019;16:412\u20134.","journal-title":"Urol J"},{"key":"3143_CR13","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","volume":"396","author":"JS Abramson","year":"2020","unstructured":"Abramson JS, Palomba ML, Gordon LI, et\u00a0al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL001): a multicentre seamless design study. Lancet. 2020;396:839\u201352.","journal-title":"Lancet"},{"key":"3143_CR14","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1200\/JCO.19.00172","volume":"38","author":"LH Sehn","year":"2020","unstructured":"Sehn LH, Herrera AF, Flowers CR, et\u00a0al. Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol. 2020;38:155\u201365.","journal-title":"J Clin Oncol"},{"key":"3143_CR15","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1056\/NEJMoa1807315","volume":"379","author":"R Advani","year":"2018","unstructured":"Advani R, Flinn I, Popplewell L, et\u00a0al. CD47 blockade by Hu5F9-G4 and rituximab in non-Hodgkin\u2019s lymphoma. N Engl J Med. 2018;379:1711\u201321.","journal-title":"N Engl J Med"},{"key":"3143_CR16","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1056\/NEJMra2027612","volume":"384","author":"LH Sehn","year":"2021","unstructured":"Sehn LH, Salles G. Diffuse large B-cell lymphoma. N Engl J Med. 2021;384:842\u201358.","journal-title":"N Engl J Med"},{"key":"3143_CR17","doi-asserted-by":"publisher","first-page":"3291","DOI":"10.1200\/JCO.19.01389","volume":"37","author":"P Armand","year":"2019","unstructured":"Armand P, Rodig S, Melnichenko V, et\u00a0al. Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma. J Clin Oncol. 2019;37:3291\u20139.","journal-title":"J Clin Oncol"},{"key":"3143_CR18","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/0090-4295(88)90241-5","volume":"32","author":"K Kerbl","year":"1988","unstructured":"Kerbl K, Pauer W. Primary non-Hodgkin lymphoma of prostate. Urology. 1988;32:347\u20139.","journal-title":"Urology"},{"key":"3143_CR19","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJM199309303291402","volume":"329","author":"International Non-Hodgkin's Lymphoma Prognostic Factors Project","year":"1993","unstructured":"International Non-Hodgkin\u2019s Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin\u2019s lymphoma. N Engl J Med. 1993;329:987\u201394.","journal-title":"N Engl J Med"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-021-03143-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13256-021-03143-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-021-03143-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,3]],"date-time":"2021-11-03T00:03:48Z","timestamp":1635897828000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-021-03143-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,3]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["3143"],"URL":"https:\/\/doi.org\/10.1186\/s13256-021-03143-3","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,3]]},"assertion":[{"value":"26 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"546"}}